Is Buying Pfizer Stock Right Now a Mistake?

NYSE: PFE | Pfizer Inc. News, Ratings, and Charts

PFE – Popular pharmaceutical company Pfizer (PFE) has entered into an agreement with the U.S. government to provide more COVID-19 vaccines. However, the stock is down more than 13% this year. Hence, will it be wise to invest in the stock now? Read on to find out….

Pfizer Inc. (PFE - Get Rating) is a well-known developer and distributor of biopharmaceutical products like medicines, vaccines, and other therapies. The company developed the Pfizer-BioNTech COVID-19 vaccine with BioNTech SE (BNTX).

On June 29, PFE and BNTX announced their new agreement with the U.S. government to provide 105 million doses of the COVID-19 vaccine, which might include adult Omicron-adapted COVID-19 vaccines. The government is expected to pay $3.20 billion upon receipt of the doses and has the option to purchase up to 195 million additional doses. The doses are expected to be delivered in late summer and continue into the fourth quarter.

PFE’s stock has gained 23.8% over the past year and 9.2% over the past month to close its last trading session at $50.82. However, it is down 13.9% year-to-date.

Here are the factors that could affect PFE’s performance in the near term:

Solid Bottom Line

For the fiscal first quarter of 2022, PFE’s revenues increased 76.8% year-over-year to $25.66 billion. Non-GAAP adjusted net income attributable to PFE common stockholders improved 74.5% from the same period the prior year to $9.34 billion, while non-GAAP adjusted earnings per common share attributable to PFE stockholders came in at $1.62, up 70.5% from the prior-year period.

Cheap Valuations

In terms of its forward P/E, PFE is trading at 8.48x, 67.7% lower than the industry average of 26.23x. The stock’s forward EV/EBITDA multiple of 6.29 is 53.1% lower than the industry average of 13.43. In terms of its forward EV/EBIT, it is trading at 6.98x, 58.9% lower than the industry average of 16.98x.

Wide Profit Margins

PFE’s trailing-12-month EBIT margin and EBITDA margin of 34.66% and 40.15% are 2,622.3% and 838% higher than their respective industry averages of 1.27% and 4.28%. Its trailing-12-month net income margin of 27.01% is substantially higher than the industry average of a negative 1.93%.

The stock’s trailing-12-month ROE, ROTC, and ROA of 33.65%, 17.59%, and 13.58% compare to their respective industry averages of a negative 36.02%, 19.74%, and 27.22%.

POWR Ratings Reflect Promising Prospects

PFE’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall rating of A, which equates to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.

PFE has a Value grade of A in sync with its low valuations. It also has a Growth and Quality grade of B, consistent with its solid bottom line growth in the last reported quarter and its wide profit margins.

In the 167-stock Medical – Pharmaceuticals industry, it is ranked #4.

Click here to see the additional POWR Ratings for PFE (Momentum, Stability, and Sentiment).

View all the top stocks in the Medical – Pharmaceuticals industry here.

Bottom Line

PFE has been a major beneficiary of the pandemic and continues to benefit from its vaccine rollouts. Moreover, the company possesses a solid bottom line and wide profit margins. And with analysts expecting continued growth in the near term, I think the stock might be a solid buy.

How Does Pfizer Inc. (PFE) Stack Up Against its Peers?

While PFE has an overall POWR Rating of A, one might consider looking at its industry peers, Merck & Co., Inc. (MRK - Get Rating) and Novo Nordisk A/S (NVO - Get Rating), which have an overall A (Strong Buy) rating.

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


PFE shares were trading at $50.86 per share on Thursday afternoon, up $0.04 (+0.08%). Year-to-date, PFE has declined -12.51%, versus a -15.73% rise in the benchmark S&P 500 index during the same period.


About the Author: Anushka Dutta


Anushka is an analyst whose interest in understanding the impact of broader economic changes on financial markets motivated her to pursue a career in investment research. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
PFEGet RatingGet RatingGet Rating
MRKGet RatingGet RatingGet Rating
NVOGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Stock Market Update: It’s Complicated!

The S&P 500 (SPY) may have bounced 17% from recent lows, but the outlook for stocks from here is...in a word...COMPLICATED. Read on to get Steve Reitmeister full market outlook and trading plan for this complicated market environment.

Becoming More Bullish on Stocks, But...

Stocks are on a roll with the S&P 500 (SPY) up more than 10% from the recent lows. Before you start getting too giddy, you should read this updated market outlook and trading plan Steve Reitmeister.

Stock Market Held Hostage

Uncertainty is the term most often applied to this stock market. Uncertainty over tariffs. Uncertainty of whether the S&P 500 (SPY) will fall into bear territory. Uncertainty over what happens next. Steve Reitmeister dives into the uncertainty to make sense of the market in this week’s commentary...

Stock Market Standing on the 50 Yard Line

Steve Reitmeister contemplates where the stock market stands now and what happens next in trying to stay on the right side of the market action. One path points to bear and one to new highs for the S&P 500 (SPY). Which will it be?

Bear or Bull Market?

The S&P 500 is on the brink of bear market territory...but that outcome is not a given at this time. Steve Reitmeister shares insights gleaned from his 45 years of investing to shine a light on current conditions along with his top picks...

Read More Stories

More Pfizer Inc. (PFE) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All PFE News